DrugPatentWatch Database Preview
Daiichi Sankyo Inc Company Profile
What is the competitive landscape for DAIICHI SANKYO INC, and when can generic versions of DAIICHI SANKYO INC drugs launch?
DAIICHI SANKYO INC has six approved drugs.
There are thirteen US patents protecting DAIICHI SANKYO INC drugs.
There are two hundred and sixty-one patent family members on DAIICHI SANKYO INC drugs in forty-three countries and eighteen supplementary protection certificates in thirteen countries.
Summary for Daiichi Sankyo Inc
| International Patents: | 261 |
| US Patents: | 13 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 6 |
| Patent Litigation for Daiichi Sankyo Inc: | See patent lawsuits for Daiichi Sankyo Inc |
Drugs and US Patents for Daiichi Sankyo Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-002 | Oct 2, 2015 | RX | Yes | No | 7,955,619 | Start Trial | Y | Start Trial | |||
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-003 | Jan 8, 2015 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-001 | Oct 2, 2015 | RX | Yes | No | 10,314,788 | Start Trial | Y | Start Trial | |||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | RX | Yes | Yes | 8,404,700 | Start Trial | Y | Start Trial | |||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | RX | Yes | Yes | 9,802,932 | Start Trial | Y | Start Trial | |||
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-003 | Jan 8, 2015 | RX | Yes | Yes | 7,365,205 | Start Trial | Y | Start Trial | |||
| Daiichi Sankyo Inc | WELCHOL | colesevelam hydrochloride | BAR, CHEWABLE;ORAL | 210895-001 | Apr 3, 2019 | RX | Yes | Yes | 7,229,613 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Daiichi Sankyo Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | EVOXAC | cevimeline hydrochloride | CAPSULE;ORAL | 020989-002 | Jan 11, 2000 | 4,855,290 | Start Trial |
| Daiichi Sankyo Inc | EVOXAC | cevimeline hydrochloride | CAPSULE;ORAL | 020989-002 | Jan 11, 2000 | 5,580,880 | Start Trial |
| Daiichi Sankyo Inc | EVOXAC | cevimeline hydrochloride | CAPSULE;ORAL | 020989-002 | Jan 11, 2000 | 5,340,821 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for DAIICHI SANKYO INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 15 mg, 30 mg, 60 mg and 100 mg | ➤ Subscribe | 2019-01-28 |
| ➤ Subscribe | Tablets | 625 mg | ➤ Subscribe | 2009-07-01 |
| ➤ Subscribe | Capsules | 30 mg | ➤ Subscribe | 2009-02-27 |
| ➤ Subscribe | Tablets | 15 mg, 30 mg and 60 mg | ➤ Subscribe | 2019-01-28 |
| ➤ Subscribe | Powder for Oral Suspension | 1.875 g/Packet and 3.75 g/Packet | ➤ Subscribe | 2010-04-09 |
International Patents for Daiichi Sankyo Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 528831 | Start Trial |
| Japan | 2019147828 | Start Trial |
| Japan | 2004526778 | Start Trial |
| Brazil | PI0721137 | Start Trial |
| Norway | 20040557 | Start Trial |
| South Korea | 20040018358 | Start Trial |
| Russian Federation | 2470637 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Daiichi Sankyo Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2140867 | C20180004 00246 | Estonia | Start Trial | PRODUCT NAME: EDOKSABAAN;REG NO/DATE: EU/1/15/993 23.06.2015 |
| 2140867 | PA2018005 | Lithuania | Start Trial | PRODUCT NAME: EDOKSABANAS, JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ARBA BET KURIO IS JU HIDRATAS, YPAC EDOKSABANO P-TOLUENSULFONATO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
| 1405852 | 15C0068 | France | Start Trial | PRODUCT NAME: EDOXABAN,UN SEL,SOLVATE OU N-OXYDE DE CELUI-CI,EN PARTICULIER L'EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993 20150619 |
| 1405852 | 122015000077 | Germany | Start Trial | PRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
| 0764174 | SPC/GB04/031 | United Kingdom | Start Trial | PRODUCT NAME: COLESEVELAM HYDROCHLORIDE; REGISTERED: UK EU/1/03/268/001-003 20040310 |
| 1685839 | 92292 | Luxembourg | Start Trial | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| 1405852 | CR 2015 00052 | Denmark | Start Trial | PRODUCT NAME: EDOXABAN, OR A SALT THEREOF, A SOLVATE THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REG. NO/DATE: EU/1/15/993/001-028 20150623 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
